The CRISPR Medicine Conference

Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).

For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.

Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.

Google Scholar ORCIID Lab Webpage

Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.

Google Scholar ORCIID LinkedIn Lab Webpage

CEO at Cellectis.

LinkedIn Company Webpage

Head of Genomic Medicine at Bayer.

ORCIID LinkedIn Company Webpage

CSO at Verve Therapeutics and Co-Founder at Corner Therapeutics

LinkedIn Company Webpage

Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget) and Professor at the Vita-Salute San Raffaele University in Milano, Italy. Co-founder of Chroma Medicine.

Google Scholar ORCIID Lab Webpage Company Webpage

Professor. and Vice-Director of Department at University of Trento, and Co-Founder of Alia Therapeutics.

Google Scholar ORCIID LinkedIn Lab Webpage

CEO and Co-founder at INTEGRA Therapeutics.

Google Scholar ORCIID LinkedIn Company Webpage

Principal Investigator and Group leader at Bar-Ilan University, Israel.

Google Scholar ORCIID LinkedIn Lab Webpage

Assistant Professor at the Center for Genomic Medicine, Harvard Medical School. MGH Research Scholar at Massachusetts General Hospital.

Google Scholar ORCIID LinkedIn Lab Webpage

Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.

Google Scholar ORCIID LinkedIn Lab Webpage

CEO and Co-founder at SNIPR Biome.

LinkedIn Company Webpage

Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA.

LinkedIn Company Webpage

Prof. and Group leader at University of Copenhagen, Denmark.

Google Scholar ORCIID LinkedIn Lab Webpage

Co-Founder and Project Lead at Ariya Bio.

LinkedIn Company Webpage

Senior Scientist at the GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain.

LinkedIn Google Scholar ORCIID Lab Webpage

Corporate Vice President, PhD, RNA and Gene Therapies, Global Research Technologies at Novo Nordisk.

LinkedIn Company Website

Head of Science & Applied Research at Synthego.

ORCIID Linkedin Company Webpage

Executive Vice President and Chief Scientific Officer at Intellia Therapeutics.

Google Scholar LinkedIn Company Webpage

Prof. at Goethe University Frankfurt, Germany and CSO at Vivlion.

Google Scholar ORCIID LinkedIn Lab Webpage Company Webpage

Senior Director of Genome Engineering Team at AstraZeneca.

ORCIID LinkedIn Company Webpage

Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine.

Google Scholar ORCIID LinkedIn BREATHE Webpage KU Leuven Webpage

Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid.

Google Scholar ORCIID LinkedIn Unit Webpage

Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.

Google Scholar ORCIID LinkedIn Lab Webpage

Ass. Prof. at the Department of Biomedicine at Aahrus University and Co-Founder of UNIKUM Therapeutics.

Google Scholar ORCIID LinkedIn Lab Webpage

Leader of the Gene Editing Program at the National Institute of Standards & Technology.

Co-Founder and CSO at Broken String Biosciences.

LinkedIn Company Webpage

Vice-President of Gene Editing at Ensoma, Founder and Chief Technology Officer at Twelve Bio, Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.

ORCIID LinkedIn Company Webpage

Prof. and Director at the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg.

Google Scholar ORCIID LinkedIn Institute Webpage

Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health

Google Scholar ORCIID LinkedIn Lab Webpage

CEO and Co-founder at Eligo Bioscience.

Google Scholar LinkedIn Company Webpage

Prof. of Gene and Stem Cell Technology at Aarhus University, Denmark and Executive Director at the Lars Bolund Institute of Regenerative Medicine, China.

Google Scholar ORCIID LinkedIn Lab Webpage